Atomo completes Capital Raise and undertakes Restructure
Released
Released
Announcement PDF
ASX Announcement
24 April 2025
Atomo completes capital raise and undertakes restructure
Atomo to raise up to $3.1 million via placement and share purchase plan based
on significant support from existing shareholders
Board restructure and Operational review resulting in further cost savings
Mr Anthony May and Mr Patrick Cook join as Non-Executive Directors of
the Company
SYDNEY, Australia, 24 April 2025 - Atomo Diagnostics Limited (ASX - AT1) announces that
it has completed a Share Placement and will now implement changes to its board and
business operations to reflect the company’s strategic and operational needs moving forward.
CAPITAL RAISE
With significant support from existing key shareholders, the Company is undertaking a capital
raising to raise up to $3.1 million, by way of a placement to raise up to $2.1 million
(“Placement”) and a share purchase plan (“SPP”) to raise up to $1.0 million (together known
as ”Capital Raising”).
The Placement will result in the issuance of approximately 112 million new fully paid ordinary
shares (“Shares”) at an issue price of $0.0185 (1.85 cents) per share with one free attaching
option, exercisable at $0.04 (4 cents) expiring 3 years from the date of issue, for every new
share subscribed for and issued ("Options") with the issuance of Options subject to
shareholder approval. The issue price of $0.0185 represents a 6% discount to the 15-day
VWAP of $0.0195.
The funds are being raised to meet the general working capital requirements, with specific use
to be determined upon the board renewal.
ACN 142 925 684
Atomo Diagnostics Limited
Level 1, 3-5 George St Leichhardt NSW 2040
New shares issued under the Capital Raising will rank equally with the shares already on issue
and the Company will apply to the ASX for quotation of the new shares, however the Options
will remain unlisted.
Placement
The Company has received binding commitments for the purchase of new shares under the
following placements, described as Tranche 1 and Tranche 2:
Tranche 1 Placement to raise approximately $833,000 through the issue of 45 million
new Shares in the Company at $0.0185 per Share and 45 million Options, to new and
existing sophisticated and professional investors under section 708 of the Corporations
Act 2001 (Cth), under the Company existing Placement Capacity under ASX Listing
Rule 7.1;
Subject to the receipt of shareholder approval, Tranche 2 Placement will raise
approximately $1.28 million through the issue of 67 million Shares in the Company at
$0.0185 per Share and 67 million Options.
The Company will apply for quotation for the new Shares (subject to the conditions of the ASX
Listing Rules). The Placement was undertaken by the Company with broker support for new
shares subscribed for by new investors. A 6% broker fee was incurred on new investor shares
totalling 4.3 million shares.
Share Purchase Plan
In addition to the Placement, the Company will also offer eligible shareholders with a
registered address in Australia or New Zealand the opportunity to participate in a share
purchase plan (“SPP”) for new fully paid ordinary shares (“SPP Shares”) at the same issue
price as the Placement with one "free" attaching New Option for every 1 SPP Share
subscribed for and issued (‘SPP Securities”). Eligibility for the SPP was determined at
7:00pm on 23 April 2025.
Eligible shareholders will be entitled to apply for up to A$30,000 worth of SPP Shares,
targeting an SPP raise of up to A$1.0 million before costs. Full details of the SPP, including
any scale back of applications in the event of oversubscriptions, will be contained in the SPP
Prospectus which is expected to be despatched on or around 20 May 2025. The issuance of
New Options under the SPP will be subject to shareholder approval.
ACN 142 925 684
Atomo Diagnostics Limited
Level 1, 3-5 George St Leichhardt NSW 2040
The SPP is not underwritten.
The Company's Directors reserve the right to participate in the SPP with Managing Director
John Kelly committed to subscribe for the maximum of A$30,000 worth of SPP Shares. Any
issues of SPP Securities to Directors or their nominees will be subject to shareholder approval.
The Company will apply for quotation for the Placement Shares and SPP Shares (subject to
the conditions of the ASX Listing Rules), however the New Options will remain unlisted.
COMPANY RESTRUCTURE
Following a comprehensive review undertaken by the Board and the Company earlier in the
year, the Board and business operations restructure to result in a restructure with associated
cost savings comprises the following:
Board Restructure
The Board will proceed with the following Director changes, resulting in a reduction to four
directors on the Board:
o
Directors Ms Deborah Neff, Dr Paul Kasian and Mr John Keith will resign from their
positions as Directors of the Company effective 2 May 2025.
o
Mr. Anthony May and Mr Patrick Cook will join the Board as Non-Executive Directors
effective 2 May 2025.
Mr May has held various Director roles across international corporations including Hoechst
Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With
extensive experience across public and private pathology laboratories, as well as sales and
management roles in the IVD supply sector, he has built a strong track record in business
leadership and strategic growth. Mr May is a member of the Australasian Association for
Clinical Biochemistry and Laboratory Medicine and holds a bachelor’s degree in science.
Mr Cook is an experienced Non-Executive Director and Chair with over 20 years of boardlevel experience and over 30 years experience in senior executive positions in medical
devices & point-of-care diagnostics sectors within multinational and listed biotechnology
companies Mr Cook currently serves as Non-Executive Director & previously Chair, at
Workplace Drug Testing Australasia Ltd and as Committee Member & previously Member of
the Executive at Animal Ethics Committee QUT. He previously served as Non-Executive
ACN 142 925 684
Atomo Diagnostics Limited
Level 1, 3-5 George St Leichhardt NSW 2040
Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of
Australia (Qld), Mr Cook is a Fellow of the Australian Institute of Company Directors and holds
degrees in Science and Marketing.
Operational Review
Complete review of operational costs across all business areas resulting in new initiatives
which will realise additional annualised savings of more than $500,000 during FY2026, over
and above the already implemented savings initiatives totalling $1.0 million over the last 18
months. None of the initiatives will impede the execution of Atomo’s key revenue and growth
drivers.
The intended timetable for the Placement and SPP is as follows:
Event
Date
Record date for SPP
7:00pm on Wednesday, 23 April 2025
Capital Raising announced, and trading halt lifted
Settlement of Offer Securities under Tranche 1 and Board
changes take effect
Allotment of Offer Securities under Tranche 1
Thursday, 24 April 2025
Friday, 2 May 2025
Monday, 5 May 2025
Despatch of Notice of Meeting, Prospectus and SPP Open
Date
Tuesday, 20 May 2025
General Meeting to approve Tranche 2 and New Options
under the SPP
Friday, 20 June 2025
SPP Close Date
Monday, 23 June 2025
Settlement of Offer Securities under Tranche 2
Thursday, 26 June 2025
Allotment of SPP Offer Securities and Offer Securities
under Tranche 2
Friday, 27 June 2025
*The above timetable is indicative only and subject to change. The quotation of new shares is subject to ASX
approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserves
the right to vary these dates, without notice. Any extension of the SPP will have a consequential effect on the issue
date of the new shares.
Board Chairman John Keith said “Following feedback shared during the November AGM, and
in consultation with significant shareholders, we believe that the actions we are taking result
in a leaner, more agile company, one better fitting with the current business environment. The
Company’s priority is to bring about growth and so accelerate generating positive operational
cash flow. The Board recognises and thanks shareholders for their extended support and trust
in the Company. On behalf of the Board and the Company, I recognise and warmly thank
ACN 142 925 684
Atomo Diagnostics Limited
Level 1, 3-5 George St Leichhardt NSW 2040
Deborah and Paul for their committed service and contribution to the Company. They have
been tireless in such efforts and more recently integral to the changes that the Company is
announcing today. As I join those directors announcing their retirement from the Board, I
applaud the Company’s achievements and recognise the management’s commitment to the
Company, thanking Shareholders for their support of the Company through these changes
and welcoming this to continue for incoming and remaining directors.”
Managing Director John Kelly said “We are excited about our future. We have over the last 12
months with great rigor reviewed all projects and roles within the company and prioritised what
will deliver the biggest impact for Atomo. I am confident we can deliver our most important
strategic imperatives whilst running the leanest possible fit for future organisation”. Mr Kelly
added “I would like to extend my sincere gratitude to Mr John Keith, our outgoing chairman,
for his dedicated service and leadership during his tenure. He has been a champion for Atomo
and has helped the company grow from a start up to a listed company now delivering improved
diagnostics to vulnerable communities around the world. I would also like to thank Deborah
Neff and Paul Kaisen for their extensive efforts on the board and leadership chairing key board
committees at Atomo.”
For more information, please contact:
John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279
This announcement was authorised by the Managing Director & CEO.
About Atomo
Atomo is an Australian headquartered medical device company supplying unique, integrated rapid
diagnostic test (RDT) devices to the global diagnostic market.
Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability
across rapid point-of-care (POC) and at-home testing applications. The Company has successfully
commercialised a number of products across international markets and has supply agreements in place
for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial
differentiation, as well as the early detection of pregnancy.
See more at www.atomodiagnostics.com
ACN 142 925 684
Atomo Diagnostics Limited
Level 1, 3-5 George St Leichhardt NSW 2040
Share your feedback
Discover